基于药学信息数据库评价肺癌治疗药物的相互作用

Evaluation of Drug-drug Interactions in Therapeutic Agents for Lung Cancer by Pharmaceutical Information Databases

目的评价肺癌治疗药物的药物相互作用(DDI)。方法在Lexicomp和Micromedex两个数据库中检索中国临床肿瘤学会《原发性肺癌诊疗指南》(2018版)所涉及的全部肺癌治疗药物的DDI,并进行归纳分析。结果25种肺癌治疗药物在Lexicomp中提示存在931对DDI,在Micromedex中则为349对,其中达到禁忌级别的分别为170对和47对。Lexicomp显示抗肿瘤植物药的DDI最多,平均每种药物的DDI数量为70对。结论对于存在多种基础疾病以及使用酪氨酸激酶抑制剂的患者,临床药师应对其进行药物治疗方案整理与优化,避免因DDI引起药物不良反应或导致疗效下降。

Objective To evaluate and analyze the drug-drug interactions(DDI)of different drugs for lung cancer treatment.Methods Pharmaceutical information databases,Lexicompand Micromedex,were used to evaluate DDI for 25 drugs for lung cancer treatment recommended by guidelines for lung cancer(2018).Results Nine hundred and thirty one DDIs were identified in Lexicomp and 349 in Micromedex.170(Lexicomp)and 47(Micromedex)medication combinations were classified as category X,which should be avoided to use together.The quantities of DDIs in plants products was the most.Conclusion Patients with cardiovascular diseases or infectious diseases and those who use tyrosine kinase inhibitors had high risk to occur DDI.Clinical pharmacists should pay more attention on these patients to avoid the adverse drug reactions during therapy.